Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Geynisman

Showing results (31-40 of 181) with videos related to

Pageof 19
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
The Year 2076Daniel M Geynisman
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
Open MindDaniel M Geynisman
JAAPA : Official Journal of the American Academy of Physician Assistants|March 29, 2020
Incidentally discovered primary mediastinal germ cell tumorVictoria Wong, Daniel M Geynisman
Translational Andrology and Urology|November 13, 2025
Checkmate 274: expanding treatment options for muscle-invasive bladder cancerHiten Doshi, Daniel M Geynisman
Journal of the National Comprehensive Cancer Network : JNCCN|May 15, 2026
JNCCN Is Moving OnlineKimberly Callan, Daniel M Geynisman
European Urology|June 25, 2022
Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial CarcinomaBenjamin Miron, Daniel M Geynisman
European Urology|September 18, 2016
Patient-reported and Cost-effectiveness Outcomes Are Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell CarcinomaBenjamin T Ristau, Daniel M Geynisman
JAMA Oncology|January 1, 2016
Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients?Daniel M Geynisman, Yu-Ning Wong
Discovery Medicine|May 3, 2013
Adherence to targeted oral anticancer medicationsDaniel M Geynisman, Karen E Wickersham
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2016
Targeted Therapy for Metastatic Urothelial Cancer: A Work in ProgressElizabeth R Plimack, Daniel M Geynisman
Pageof 19

Showing results (31-40 of 181) with videos related to

Sort By:
Pageof 19
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
The Year 2076Daniel M Geynisman
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
Open MindDaniel M Geynisman
JAAPA : Official Journal of the American Academy of Physician Assistants|March 29, 2020
Incidentally discovered primary mediastinal germ cell tumorVictoria Wong, Daniel M Geynisman
Translational Andrology and Urology|November 13, 2025
Checkmate 274: expanding treatment options for muscle-invasive bladder cancerHiten Doshi, Daniel M Geynisman
Journal of the National Comprehensive Cancer Network : JNCCN|May 15, 2026
JNCCN Is Moving OnlineKimberly Callan, Daniel M Geynisman
European Urology|June 25, 2022
Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial CarcinomaBenjamin Miron, Daniel M Geynisman
European Urology|September 18, 2016
Patient-reported and Cost-effectiveness Outcomes Are Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell CarcinomaBenjamin T Ristau, Daniel M Geynisman
JAMA Oncology|January 1, 2016
Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients?Daniel M Geynisman, Yu-Ning Wong
Discovery Medicine|May 3, 2013
Adherence to targeted oral anticancer medicationsDaniel M Geynisman, Karen E Wickersham
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2016
Targeted Therapy for Metastatic Urothelial Cancer: A Work in ProgressElizabeth R Plimack, Daniel M Geynisman
Pageof 19